一项3期随机对照开放标签研究:评估12-14月龄儿童接种1剂或2剂MenACWY-TT脑膜炎球菌结合疫苗(联用或不联用13价肺炎球菌结合疫苗)后免疫持久性至5年
该3期随机对照开放标签研究纳入802名12-24月龄健康儿童,随机分为1剂MenACWY-TT组、2剂MenACWY-TT组、MenACWY-TT与PCV13同时接种组、PCV13后接种MenACWY-TT组,评估初免后1、3、5年的rSBA滴度≥1:8百分比和GMTs。结果显示抗体应答随时间下降,但5年时仍高于接种前水平;5年时各组各血清群rSBA滴度≥1:8百分比分别为20.5%-58.6%、28.4%-65.8%、23.9%-52.8%、19.4%-55.8%。1剂与2剂MenACWY-TT的抗体持久性相当,但2剂组GMTs更高;联用PCV13与仅接种MenACWY-TT的 protective 抗体百分比相似;未发现新的安全性问题。
要点
- 5年时各组各血清群rSBA滴度≥1:8百分比分别为20.5%-58.6%、28.4%-65.8%、23.9%-52.8%、19.4%-55.8%。
- 1剂与2剂MenACWY-TT的5年抗体持久性相当,但2剂组GMTs更高。
- 联用PCV13与仅接种MenACWY-TT的5年保护性抗体百分比相似。
核心结论
- 多数儿童在接种1剂或2剂MenACWY-TT(联用或不联用PCV13)后抗体应答持续至5年,未发现新的安全性问题。
研究设计与样本
- 3期随机对照开放标签研究,纳入802名12-24月龄健康儿童,随机分为ACWY1d组(0月接种MenACWY-TT)、ACWY2d组(0和2月接种MenACWY-TT)、Co-Ad组(0月同时接种MenACWY-TT和PCV13)、PCV13/ACWY组(0月接种PCV13,2月接种MenACWY-TT)。
- 初免后1、3、5年采用兔补体血清杀菌试验(rSBA)评估滴度≥1:8百分比和几何平均滴度(GMTs),并报告初免后至5年的严重不良事件。
- 619名儿童完成至5年的研究。
主要发现
- 接种后免疫应答随时间下降,但5年时仍高于接种前水平。
- 5年时各血清群rSBA滴度≥1:8百分比:ACWY1d组20.5%-58.6%,ACWY2d组28.4%-65.8%,Co-Ad组23.9%-52.8%,PCV13/ACWY组19.4%-55.8%。
- 1剂与2剂MenACWY-TT的5年抗体持久性相当,但2剂组GMTs高于1剂组。
- 联用PCV13与仅接种1剂或2剂MenACWY-TT的5年保护性抗体百分比相似。
- 研究期间未发现新的安全性问题。
关键数值与推荐
- 5年时各血清群rSBA滴度≥1:8百分比:ACWY1d组20.5%-58.6%,ACWY2d组28.4%-65.8%,Co-Ad组23.9%-52.8%,PCV13/ACWY组19.4%-55.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunogenicity and safety up to 5 years after administration of 1 or 2 doses of quadrivalent meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) given alone or with 13-valent pneumococcal conjugate vaccine (PCV13) in children was investigated. METHODS: This phase 3 study randomized healthy 12-24-month-olds to MenACWY-TT at Month 0 (ACWY1d), MenACWY-TT at Months 0 and 2 (ACWY2d), MenACWY-TT and PCV13 at Month 0 (Co-Ad), or PCV13 at Month 0 and MenACWY-TT at Month 2 (PCV13/ACWY). Immune responses 1, 3, and 5 years after primary vaccination were evaluated with serum bactericidal activity using rabbit complement (rSBA) titers ≥ 1:8 and geometric mean titers (GMTs). Evaluation of serious adverse events up to 5 years after primary vaccination are reported. RESULTS: Of the 802 children randomized in the study, 619 completed the study through Year 5. Immune responses after vaccination declined over time but were higher 5 years after vaccination compared with levels before vaccination. At Year 5, the percentages of children with rSBA titers ≥ 1:8 across all serogroups were 20.5 %-58.6 %, 28.4 %-65.8 %, 23.9 %-52.8 %, and 19.4 %-55.8 % in the ACWY1d, ACWY2d, Co-Ad, and PCV13/ACWY groups, respectively. Comparable antibody persistence at Year 5 was observed for participants receiving 1 or 2 doses of MenACWY-TT, although GMTs were elevated in those who received 2 versus 1 dose. The percentage of children with protective antibody titers at Year 5 was similar in participants who received PCV13 and MenACWY-TT compared with that observed for participants who only received 1 or 2 MenACWY-TT doses. No new safety concerns were identified during the study period. CONCLUSION: Antibody responses persisted in the majority of children up to 5 years after primary vaccination with MenACWY-TT administered in a 1- or 2-dose regimen with or without PCV13, with no new safety concerns identified. CLINICALTRIALS: gov Identifier NCT01939158; EudraCT number 2013-001083-28.
引用
- Cutland CL, Peyrani P, Webber C, et al. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children. Vaccine. 2023. PMID: 36621408. doi:10.1016/j.vaccine.2022.11.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。